Article Data

  • Views 498
  • Dowloads 175

Rapid Reports

Open Access

Analysis of the performances of the Covid-19 therapeutic approaches in the United Arab Emirates

  • Alberto Boretti1

1Deanship of Research, Prince Mohammad Bin Fahad University, Al Khobar, Saudi Arabia

DOI: 10.22514/sv.2021.041 Vol.17,Issue 3,May 2021 pp.256-263

Submitted: 22 January 2021 Accepted: 04 February 2021

Published: 08 May 2021

*Corresponding Author(s): Alberto Boretti E-mail:


Objectives: To evaluate the performances of the therapeutic approaches adopted in the United Arab Emirates to fight Covid-19 infection.

Methods: Statistical analysis of the number of cases and fatalities for the United Arab Emirates. The fatality rates are compared to those of reference countries adopting different approaches.

Results: The United Arab Emirates outperformed the reference countries with a much smaller number of fatalities. While this number is not only driven by therapies, the different therapeutic approaches are the most important driver.

Conclusions: Combination therapies are most effective than single drug therapies. The use of antivirals especially in the early stages reduces the number of fatalities.


Covid-19; Antivirals; Combination therapies

Cite and Share

Alberto Boretti. Analysis of the performances of the Covid-19 therapeutic approaches in the United Arab Emirates. Signa Vitae. 2021. 17(3);256-263.


[1] Wang Y, Zhang L, Sang L, Ye F, Ruan S, Zhong B, et al. Kinetics of viral load and antibody response in relation to COVID-19 severity. Journal of Clinical Investigation. 2020; 130: 5235-5244.

[2] Xu T, Chen C, Zhu Z, Cui M, Chen C, Dai H, et al. Clinical features and dynamics of viral load in imported and non-imported patients with COVID-19. International Journal of Infectious Diseases. 2020; 94: 68-71.

[3] Westblade LF, Brar G, Pinheiro LC, Paidoussis D, Rajan M, Martin P, et al. SARS-CoV-2 viral load predicts mortality in patients with and without cancer who are hospitalized with COVID-19. Cancer Cell. 2020; 38: 661- 671. e2.


[5] Kumar R, Sharma A, Srivastava JK, Siddiqui MH, Uddin MS, Aleya L. Hydroxychloroquine in COVID-19: therapeutic promises, current status, and environmental implications. Environmental Science and Pollution Research. 2021; 1-14.

[6] Kumar R, Srivastava JK, Singh R, Siddiqui MH, Mansouri RA, Abdulhakim JA, et al. Available Compounds with Therapeutic Potential against COVID-19: antimicrobial therapies, supportive care and probable vaccines. Frontiers in pharmacology. 2020; 11: 1592.

[7] Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. Journal of the American Medical Association. 2020; 323: 1824-1836.

[8] Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosup-pressed states: a clinical-therapeutic staging proposal. The Journal of Heart and Lung Transplantation. 2020; 39: 405-407.

[9] Boretti A. Favipiravir use for SARS CoV-2 infection. Pharmacological Reports. 2020; 72: 1542-1552.

[10] Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental Treatment with Favipiravir for COVID-19: an open-label control study. Engineering. 2020; 6: 1192-1198.

[11] Lou Y, Liu L, Yao H, Hu X, Su J, Xu K, et al. Clinical Outcomes and plasma concentrations of baloxavir marboxil and favipiravir in COVID-19 patients: an exploratory randomized, controlled trial. European Journal of Pharmaceutical Sciences. 2021; 157: 105631.

[12] Yamamura H, Matsuura H, Nakagawa J, Fukuoka H, Domi H, Chujoh S. Effect of favipiravir and an anti-inflammatory strategy for COVID-19. Critical Care. 2020; 24: 413.

[13] Breining P, Frølund AL, Højen JF, Gunst JD, Staerke NB, Saedder E, et al. Camostat mesylate against SARS-CoV-2 and COVID-19-rationale, dosing and safety. Basic & Clinical Pharmacology & Toxicology. 2021; 128: 204-212.

[14] Hofmann-Winkler H, Moerer O, Alt-Epping S, Bräuer A, Büttner B, Müller M, et al. Camostat mesylate may reduce severity of coronavirus disease 2019 sepsis: a first observation. Critical Care Explorations. 2020; 2: e0284.

[15] Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. New England Journal of Medicine. 2020; 382: 1787-1799.

[16] Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, et al. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. Journal of Korean Medical Science. 2020; 35: e79.

[17] Horby PW, Mafham M, Bell JL, Linsell L, Staplin N, Emberson J, et al. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet. 2020; 396: 1345-1352.

[18] Khalili JS, Zhu H, Mak NSA, Yan Y, Zhu Y. Novel coronavirus treatment with ribavirin: groundwork for an evaluation concerning COVID-19. Journal of Medical Virology. 2020; 92: 740-746.

[19] Tong S, Su Y, Yu Y, Wu C, Chen J, Wang S, et al. Ribavirin therapy for severe COVID-19: a retrospective cohort study. International Journal of Antimicrobial Agents. 2020; 56: 106114.

[20] Eslami G, Mousaviasl S, Radmanesh E, Jelvay S, Bitaraf S, Simmons B, et al. The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19. Journal of Antimicrobial Chemotherapy. 2020; 75: 3366-3372.

[21] Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19-final report. New England Journal of Medicine. 2020; 383: 1813-1826.

[22] Al-Tawfiq JA, Al-Homoud AH, Memish ZA. Remdesivir as a possible therapeutic option for the COVID-19. Travel Medicine and Infectious Disease. 2020; 34: 101615.

[23] McCreary EK, Angus DC. Efficacy of remdesivir in COVID-19. Journal of the American Medical Association. 2020; 324: 1041-1042.

[24] Zhong J, Tang J, Ye C, Dong L. The immunology of COVID-19: is immune modulation an option for treatment? The Lancet Rheumatology. 2020; 2: e428-e436.

[25] Ellison-Hughes GM, Colley L, O’Brien KA, Roberts KA, Agbaedeng TA, Ross MD. The role of MSC therapy in attenuating the damaging effects of the cytokine storm induced by COVID-19 on the heart and cardiovascular system. Frontiers in cardiovascular medicine. 2020; 7: 602183.

[26] Marovich M, Mascola JR, Cohen MS. Monoclonal antibodies for prevention and treatment of COVID-19. Journal of the American Medical Association. 2020; 324: 131-132.

[27] Monteagudo LA, Boothby A, Gertner E. Continuous intravenous anakinra infusion to calm the cytokine storm in macrophage activation syndrome. ACR Open Rheumatology. 2020; 2: 276-282.

[28] Monteagudo LA, Boothby A, Gertner E. Continuous intravenous anakinra infusion to calm the cytokine storm in macrophage activation syndrome. ACR Open Rheumatology. 2020; 2: 276-282.

[29] Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proceedings of the National Academy of Sciences. 2020; 117: 10970-10975.

[30] Zhou Q, Wei XS, Xiang X, Wang X, Wang ZH, Chen V, et al. Interferon-α2b treatment for COVID-19. 2020; MedRxiv.

[31] Cao Y, Wei J, Zou L, Jiang T, Wang G, Chen L, et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology. 2020; 146: 137-146.e3.

[32] Lee JS, Shin E. The type I interferon response in COVID-19: implications for treatment. Nature Reviews Immunology. 2020; 20: 585-586.

[33] Zhou Q, Chen V, Shannon CP, Wei XS, Xiang X, Wang X, et al. Interferon-α2b treatment for COVID-19. Frontiers in Immunology. 2020; 11: 1061.

[34] Davoudi-Monfared E, Rahmani H, Khalili H, Hajiabdolbaghi M, Salehi M, Abbasian L, et al. A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19. Antimicrobial Agents and Chemotherapy. 2020; 64: e01061-20.

[35] Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. Journal of the American College of Cardiology. 2020; 75: 2950-2973.

[36] Chaudhary R, Kreutz RP, Bliden KP, Tantry US, Gurbel PA. Personal-izing antithrombotic therapy in COVID-19: role of thromboelastography and thromboelastometry. Thrombosis and Haemostasis. 2020; 120: 1594-1596.

[37] Boretti A, Banik BK. Intravenous vitamin C for reduction of cytokines storm in acute respiratory distress syndrome. PharmaNutrition. 2020; 12: 100190.

[38] Cheng RZ. Can early and high intravenous dose of vitamin C prevent and treat coronavirus disease 2019 (COVID-19)? Medicine in Drug Discovery. 2020; 5: 100028.

[39] Cereda E, Bogliolo L, de Stefano L, Caccialanza R. A brief discussion of the benefit and mechanism of vitamin D supplementation on coronavirus disease 2019. Current Opinion in Clinical Nutrition & Metabolic Care. 2021; 24: 102-107.

[40] Meltzer DO, Best TJ, Zhang H, Vokes T, Arora V, Solway J. Association of vitamin D status and other clinical characteristics with COVID-19 test results. JAMA Network Open. 2020; 3: e2019722.

[41] Anuk AT, Polat N, Akdas S, Erol SA, Tanacan A, Biriken D, et al. The relation between trace element status (zinc, copper, magnesium) and clinical outcomes in COVID-19 infection during pregnancy. Biological trace element research. 2020; 1-10.

[42] Wessels I, Rolles B, Rink L. The potential impact of zinc supplementation on COVID-19 pathogenesis. Frontiers in Immunology. 2020; 11: 1712.

[43] HCQ for COVID-19. Available at:

[44] Procter BC, Ross C, Pickard V, Smith E, Hanson C, McCullough PA. Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection. Reviews in Cardiovascular Medicine. 2020; 21: 611-614.

[45] Su Y, Ling Y, Ma Y, Tao L, Miao Q, Shi Q, et al. Efficacy of early hydroxychloroquine treatment in preventing COVID-19 pneumonia aggravation, the experience from Shanghai, China. BioScience Trends. 2020; 14: 408-414.

[46] Sogut O, Can MM, Guven R, Kaplan O, Ergenc H, Umit TB, et al. Safety and efficacy of hydroxychloroquine in 152 outpatients with confirmed COVID-19: a pilot observational study. The American Journal of Emergency Medicine. 2021; 40: 41-46.

[47] Agusti A, Guillen E, Ayora A, Anton A, Aguilera C, Vidal X, et al. Efficacy and safety of hydroxychloroquine in healthcare professionals with mild SARS-CoV-2 infection: prospective, non-randomized trial. Enfermedades Infecciosas Y Microbiología ClíNica. 2020; S0213-005X(20)30413-4.

[48] Omrani AS, Pathan SA, Thomas SA, Harris TRE, Coyle PV, Thomas CE, et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe COVID-19. EClinicalMedicine. 2020; 29-30: 100645.

[49] Szente Fonseca SN, de Queiroz Sousa A, Wolkoff AG, Moreira MS, Pinto BC, Valente Takeda CF, et al. Risk of hospitalization for COVID-19 outpatients treated with various drug regimens in Brazil: comparative analysis. Travel Medicine and Infectious Disease. 2020; 38: 101906.

[50] Derwand R, Scholz M, Zelenko V. COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study. International Journal of Antimicrobial Agents. 2020; 56: 106214.

[51] Prodromos C, Rumschlag T. Hydroxychloroquine is effective, and consistently so used early, for COVID-19: a systematic review. New microbes and new infections. 2020; 38: 100776.

[52] Hong KS, Jang JG, Hur J, Lee JH, Kim HN, Lee W, et al. Early hydroxychloroquine administration for rapid severe acute respiratory syndrome coronavirus 2 eradication. Infection & Chemotherapy. 2020; 52: 396.

[53] RECOVERY. Randomised evaluation of COVID-19 therapy. 2020. Available at: (Accessed: 30 January 2021).

[54] WHO Solidarity Trial Consortium, 2020. Repurposed antiviral drugs for COVID-19-interim WHO SOLIDARITY trial results. New England Journal of Medicine. 2021; 384:497-511.

[55] RT question more. Thousands of Israelis test POSITIVE for Covid-19 despite receiving Pfizer/BioNTech jab. 2021. Available at: (Accessed: 30 January 2021).

[56] Efrati I, Linder R. Thousands of Israelis tested positive for coronavirus after first vaccine shot. Available at:

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Chemical Abstracts Service Source Index The CAS Source Index (CASSI) Search Tool is an online resource that can quickly identify or confirm journal titles and abbreviations for publications indexed by CAS since 1907, including serial and non-serial scientific and technical publications.

IndexCopernicus The Index Copernicus International (ICI) Journals database’s is an international indexation database of scientific journals. It covered international scientific journals which divided into general information, contents of individual issues, detailed bibliography (references) sections for every publication, as well as full texts of publications in the form of attached files (optional). For now, there are more than 58,000 scientific journals registered at ICI.

Geneva Foundation for Medical Education and Research The Geneva Foundation for Medical Education and Research (GFMER) is a non-profit organization established in 2002 and it works in close collaboration with the World Health Organization (WHO). The overall objectives of the Foundation are to promote and develop health education and research programs.

Scopus: CiteScore 0.5(2019) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Embase Embase (often styled EMBASE for Excerpta Medica dataBASE), produced by Elsevier, is a biomedical and pharmacological database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug.

Submission Turnaround Time